Parallax Volatility Advisers, L.P. Beam Therapeutics Inc. Transaction History
Parallax Volatility Advisers, L.P.
- $35.7 Billion
- Q1 2025
A detailed history of Parallax Volatility Advisers, L.P. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Parallax Volatility Advisers, L.P. holds 3,259 shares of BEAM stock, worth $57,847. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,259Holding current value
$57,847% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding BEAM
# of Institutions
258Shares Held
93.6MCall Options Held
425KPut Options Held
309K-
Farallon Capital Management LLC San Francisco, CA9.93MShares$176 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.87MShares$157 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.48MShares$151 Million1.79% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$136 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$80.6 Million72.77% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.25B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...